These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 35951338)

  • 1. Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19.
    Haggenburg S; Hofsink Q; Lissenberg-Witte BI; Broers AEC; van Doesum JA; van Binnendijk RS; den Hartog G; Bhoekhan MS; Haverkate NJE; Burger JA; Bouhuijs JH; Smits GP; Wouters D; van Leeuwen EMM; Bontkes HJ; Kootstra NA; Zweegman S; Kater AP; Heemskerk MHM; Groen K; van Meerten T; Mutsaers PGNJ; Beaumont T; van Gils MJ; Goorhuis A; Rutten CE; Hazenberg MD; Nijhof IS;
    JAMA Oncol; 2022 Oct; 8(10):1477-1483. PubMed ID: 35951338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients.
    Obeid M; Suffiotti M; Pellaton C; Bouchaab H; Cairoli A; Salvadé V; Stevenel C; Hottinger R; Pythoud C; Coutechier L; Molinari L; Trono D; Ribi C; Gottardo R; Fenwick C; Pascual M; Duchosal MA; Peters S; Pantaleo G
    JAMA Oncol; 2022 May; 8(5):e220446. PubMed ID: 35271706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients.
    Haggenburg S; Lissenberg-Witte BI; van Binnendijk RS; den Hartog G; Bhoekhan MS; Haverkate NJE; de Rooij DM; van Meerloo J; Cloos J; Kootstra NA; Wouters D; Weijers SS; van Leeuwen EMM; Bontkes HJ; Tonouh-Aajoud S; Heemskerk MHM; Sanders RW; Roelandse-Koop E; Hofsink Q; Groen K; Çetinel L; Schellekens L; den Hartog YM; Toussaint B; Kant IMJ; Graas T; de Pater E; Dik WA; Engel MD; Pierie CRN; Janssen SR; van Dijkman E; Poniman M; Burger JA; Bouhuijs JH; Smits G; Rots NY; Zweegman S; Kater AP; van Meerten T; Mutsaers PGNJ; van Doesum JA; Broers AEC; van Gils MJ; Goorhuis A; Rutten CE; Hazenberg MD; Nijhof IS
    Blood Adv; 2022 Mar; 6(5):1537-1546. PubMed ID: 35114690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida.
    Giuliano AR; Lancet JE; Pilon-Thomas S; Dong N; Jain AG; Tan E; Ball S; Tworoger SS; Siegel EM; Whiting J; Mo Q; Cubitt CL; Dukes CW; Hensel JA; Keenan RJ; Hwu P
    JAMA Oncol; 2022 May; 8(5):748-754. PubMed ID: 35266953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study.
    Hofsink Q; Haggenburg S; Lissenberg-Witte BI; Broers AEC; van Doesum JA; van Binnendijk RS; den Hartog G; Bhoekhan MS; Haverkate NJE; van Meerloo J; Burger JA; Bouhuijs JH; Smits GP; Wouters D; van Leeuwen EMM; Bontkes HJ; Kootstra NA; Vogels-Nooijen S; Rots N; van Beek J; Heemskerk MHM; Groen K; van Meerten T; Mutsaers PGNJ; van Gils MJ; Goorhuis A; Rutten CE; Hazenberg MD; Nijhof IS;
    EClinicalMedicine; 2023 Jul; 61():102040. PubMed ID: 37337616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study.
    Hill JA; Martens MJ; Young JH; Bhavsar K; Kou J; Chen M; Lee LW; Baluch A; Dhodapkar MV; Nakamura R; Peyton K; Howard DS; Ibrahim U; Shahid Z; Armistead P; Westervelt P; McCarty J; McGuirk J; Hamadani M; DeWolf S; Hosszu K; Sharon E; Spahn A; Toor AA; Waldvogel S; Greenberger LM; Auletta JJ; Horowitz MM; Riches ML; Perales MA
    Clin Infect Dis; 2024 Aug; 79(2):542-554. PubMed ID: 38801746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omicron-Specific Cytotoxic T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With Multiple Sclerosis Treated With Ocrelizumab.
    Madelon N; Heikkilä N; Sabater Royo I; Fontannaz P; Breville G; Lauper K; Goldstein R; Grifoni A; Sette A; Siegrist CA; Finckh A; Lalive PH; Didierlaurent AM; Eberhardt CS
    JAMA Neurol; 2022 Apr; 79(4):399-404. PubMed ID: 35212717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study.
    Hill JA; Martens MJ; Young JH; Bhavsar K; Kou J; Chen M; Lee LW; Baluch A; Dhodapkar MV; Nakamura R; Peyton K; Shahid Z; Armistead P; Westervelt P; McCarty J; McGuirk J; Hamadani M; DeWolf S; Hosszu K; Sharon E; Spahn A; Toor AA; Waldvogel S; Greenberger LM; Auletta JJ; Horowitz MM; Riches ML; Perales MA
    EClinicalMedicine; 2023 May; 59():101983. PubMed ID: 37128256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients - A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease.
    Wagner A; Garner-Spitzer E; Schötta AM; Orola M; Wessely A; Zwazl I; Ohradanova-Repic A; Weseslindtner L; Tajti G; Gebetsberger L; Kratzer B; Tomosel E; Kutschera M; Tobudic S; Pickl WF; Kundi M; Stockinger H; Novacek G; Reinisch W; Zielinski C; Wiedermann U
    Front Immunol; 2022; 13():889138. PubMed ID: 35634285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial.
    Thakkar A; Pradhan K; Duva B; Carreno JM; Sahu S; Thiruthuvanathan V; Campbell S; Gallego S; Bhagat TD; Rivera J; Choudhary G; Olea R; Sabalza M; Shapiro LC; Lee M; Quinn R; Mantzaris I; Chu E; Will B; Pirofski LA; Krammer F; Verma A; Halmos B
    Elife; 2023 Mar; 12():. PubMed ID: 36975207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the Durability of the Immune Humoral Response to COVID-19 Vaccines in Patients With Cancer Undergoing Treatment or Who Received a Stem Cell Transplant.
    Khan QJ; Bivona CR; Martin GA; Zhang J; Liu B; He J; Li KH; Nelson M; Williamson S; Doolittle GC; Sun W; Mudaranthakam DP; Streeter NR; McGuirk JP; Al-Rajabi R; Hoffmann M; Kasi A; Parikh RA; Zhong C; Mitchell L; Pessetto ZY; Pathak H; Ghosh A; LaFaver S; Sharma P; Godwin AK
    JAMA Oncol; 2022 Jul; 8(7):1053-1058. PubMed ID: 35446353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
    Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
    Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients.
    Benning L; Morath C; Bartenschlager M; Kim H; Reineke M; Beimler J; Buylaert M; Nusshag C; Kälble F; Reichel P; Töllner M; Schaier M; Klein K; Benes V; Rausch T; Rieger S; Stich M; Tönshoff B; Weidner N; Schnitzler P; Zeier M; Süsal C; Hien Tran T; Bartenschlager R; Speer C
    Am J Transplant; 2022 Jul; 22(7):1873-1883. PubMed ID: 35384272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection.
    Gilboa M; Regev-Yochay G; Mandelboim M; Indenbaum V; Asraf K; Fluss R; Amit S; Mendelson E; Doolman R; Afek A; Freedman LS; Kreiss Y; Lustig Y
    JAMA Netw Open; 2022 Sep; 5(9):e2231778. PubMed ID: 36107426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial.
    Reindl-Schwaighofer R; Heinzel A; Mayrdorfer M; Jabbour R; Hofbauer TM; Merrelaar A; Eder M; Regele F; Doberer K; Spechtl P; Aschauer C; Koblischke M; Paschen C; Eskandary F; Hu K; Öhler B; Bhandal A; Kleibenböck S; Jagoditsch RI; Reiskopf B; Heger F; Bond G; Böhmig GA; Strassl R; Weseslindtner L; Indra A; Aberle JH; Binder M; Oberbauer R
    JAMA Intern Med; 2022 Feb; 182(2):165-171. PubMed ID: 34928302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.
    Hsu CM; Weiner DE; Manley HJ; Aweh GN; Ladik V; Frament J; Miskulin D; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK
    Clin J Am Soc Nephrol; 2022 Mar; 17(3):403-413. PubMed ID: 35144972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial.
    Oosting SF; van der Veldt AAM; GeurtsvanKessel CH; Fehrmann RSN; van Binnendijk RS; Dingemans AC; Smit EF; Hiltermann TJN; den Hartog G; Jalving M; Westphal TT; Bhattacharya A; van der Heiden M; Rimmelzwaan GF; Kvistborg P; Blank CU; Koopmans MPG; Huckriede ALW; van Els CACM; Rots NY; van Baarle D; Haanen JBAG; de Vries EGE
    Lancet Oncol; 2021 Dec; 22(12):1681-1691. PubMed ID: 34767759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation.
    Huang A; Cicin-Sain C; Pasin C; Epp S; Audigé A; Müller NJ; Nilsson J; Bankova A; Wolfensberger N; Vilinovszki O; Nair G; Hockl P; Schanz U; Kouyos RD; Hasse B; Zinkernagel AS; Trkola A; Manz MG; Abela IA; Müller AMS
    Transplant Cell Ther; 2022 Apr; 28(4):214.e1-214.e11. PubMed ID: 35092892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXID.
    Chen P; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Söderdahl G; Österborg A; Smith CIE; Vesterbacka J; Wullimann D; Cuapio A; Akber M; Bogdanovic G; Muschiol S; Åberg M; Loré K; Sällberg Chen M; Buggert M; Ljungman P; Aleman S; Ljunggren HG
    EBioMedicine; 2023 Aug; 94():104700. PubMed ID: 37453361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.